Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pennsylvania State University

www.psu.edu

Latest From PharmAbcine Inc.

Promising Tanibirumab Trial Boosts PharmAbcine’s Confidence

PharmAbcine is counting on the success of its lead anticancer antibody tanibirumab following promising early Phase II results, and the South Korean bioventure is planning to raise new funds as it looks to progress this and other pipeline projects.

South Korea Business Strategies

Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs

Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.

Commercial Deals

Strong Biopharma Appetite Aids Solid Korean IPO Debuts

Shares of Green Cross LabCell and ST Pharm jumped on their debut following their successful initial public offerings earlier this month. Numerous South Korean biotechs are seeking IPOs this year amid the government's ongoing drive to nurture the biopharma sector and the stock exchange's efforts to ease listing regulations to help fund raising by promising small firms including bioventures.

BioPharmaceutical Asia Pacific

PharmAbcine Seeks Australian Fast Track For Glioblastoma Candidate

Following an initial clinical study in South Korea, PharmAbcine is progressing with Phase IIa plans in Australia for its anticancer antibody tanibirumab. The South Korean biotech expects to benefit from the country's ‘outstanding’ clinical trial system and is aiming to initially launch the drug in Australia through a fast-track approval system without a Phase III program.

BioPharmaceutical Asia Pacific
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register